What is the current price and short-term tone for 2228.HK stock?

2228.HK stock trades pre-market at **HKD 12.93** on 22 Jan 2026. Short-term momentum is bullish with RSI **76.82** and active volume, but overbought signals suggest traders watch for pullbacks to the 50-day average at **HKD 10.48**.

What forecasts and price targets exist for 2228.HK stock?

Meyka AI's forecast model projects **monthly HKD 16.04**, **quarterly HKD 11.67**, and **yearly HKD 10.46** for 2228.HK stock. These imply short-term upside but medium-term downside; forecasts are model-based projections and not guarantees.

How does XtalPi’s financial profile affect 2228.HK stock risk?

XtalPi shows revenue growth but still reports net losses and high price-to-sales metrics, which increases risk for 2228.HK stock. Cash per share is **HKD 0.92** and current ratio near **9.69**, offering liquidity but not removing execution risk.

Where can I read the company financials and recent coverage on 2228.HK stock?

Detailed company financials and recent coverage for 2228.HK stock are available at StockAnalysis, which hosts the XtalPi company page and financial breakdown [source](https://stockanalysis.com/quote/hkg/2228/).

HK Stocks

Pre-market HKD 12.93 2228.HK XtalPi (HKSE) 22 Jan 2026: AI drug discovery catalyst ahead

ByHuzaifa Zahoor January 22, 2026January 22, 2026

The 2228.HK stock opens pre-market at HKD 12.93 on 22 Jan 2026, trading near a 50-day average of HKD 10.48 and a 200-day average of HKD 8.41. Volume is active at 45,711,382 shares and market capitalisation is about HKD 55.64B on the HKSE in Hong Kong. Investors in AI-driven drug discovery should note the stock’s recent run-up, high RSI, and mixed valuation metrics. We summarise where XtalPi Holdings Ltd (2228.HK) sits on fundamentals, technicals, Meyka AI forecasts, and the key catalysts that could move the share price next